Here’s a quick update on the latest publicly reported progress in pancreatic cancer drugs:
A 2026 Northwestern-led trial reported that elraglusib, when combined with chemotherapy, doubled one-year survival compared with historical controls in metastatic pancreatic cancer, suggesting meaningful activity and encouraging further testing in larger trials. This is early-phase data and would require confirmation in a phase 3 study before changing standard of care. [Northwestern University news, 2026][5]
In 2024, FDA-approved four-drug regimens (NALIRIFOX) for first-line treatment of metastatic pancreatic adenocarcinoma, combining irinotecan liposome with oxaliplatin, leucovorin, and fluorouracil, representing a notable advancement in combination chemotherapy options. This approval followed UCLA-led research supporting improved outcomes with more intensive regimens. [FDA/NEJM-era data; UCLA press release, 2024][8][9]
Earlier reports (2019–2020s) highlighted multiple experimental approaches, including PARP inhibitors for BRCA-mutated pancreatic cancer and combinations aiming to sensitize tumors to radiation or gemcitabine, with varying degrees of success and ongoing investigation. These studies contributed to a broader search for targeted and combination strategies. [FDA approvals and related studies; 2019–2020 era reports][3][4][7]
Important context and caveats:
Would you like a concise timeline of the most recent major developments, or a quick table comparing the key approved regimens and notable trial drugs with their patient populations and line of therapy? I can tailor it to your location (Dallas, TX) and any specific molecular features you’re interested in.
A four-drug chemotherapy regimen of irinotecan liposome (Onivyde) in combination with oxaliplatin, leucovorin, and fluorouracil—together referred to as NALIRIFOX—has been approved by the U.S. Food and Drug Administration (FDA) for the first-line treatment of metastatic pancreatic adenocarcinoma.
www.eurekalert.orgThe latest Speed Read,/speed-reads,,speed-reads, breaking news, comment, reviews and features from the experts at The Week
theweek.comPancreatic cancer is one of the deadliest cancers and among the hardest to treat, with most patients surviving less than a year after diagnosis. But a new drug developed at Northwestern University may soon help patients live longer.
news.northwestern.eduA four-drug chemotherapy regimen of irinotecan liposome (Onivyde) in combination with oxaliplatin, leucovorin, and fluorouracil has been approved by the FDA for the first-line treatment of metastatic pancreatic adenocarcinoma.
www.uclahealth.orgThe FDA has approved drug a pancreatic cancer drug, Onivyde, which has produced significant overall survival rates in an international clinical study. Onivyde (irinotecan liposome injection) will be used as part of a combination regimen with two chemotherapy drugs, fluorouracil and leucovorin. It has been approved to treat patients with pancreatic cancer that has progressed after treatment with a different chemotherapy, gemcitabine-based therapy.
pharmafile.comWhile the overall cancer death rate has been steadily declining in the U.S. since the 1990s, death rates due to pancreatic cancer are increasing.
www.news-medical.netIn today’s Health Alert, a potential breakthrough in one of the deadliest cancers. A new drug is showing remarkable results in late-stage trials for pancreatic cancer.
www.wxyz.comThe U.S. Food and Drug Administration approved an ovarian cancer drug for the maintenance and treatment of pancreatic cancer, according to AstraZeneca and Merck.
www.fox32chicago.comResearchers have invented a new drug for treating pancreatic cancer, which also showed promising initial results.Radiation and the chemotherapy drug gemcitabine, which are the standard treatment for pancreatic cancer, both work by causing damage to DNA. But pancreatic cancer has a way of repairing that damage, which limits how effective these therapies can be.Rogel Cancer Center laboratory researchers, led by Meredith Morgan, PhD, found that AZD1775 prevented pancreatic cancer from protecting...
www.business-standard.com